10th annual Immuno-Oncology Summit
October 2, 2022
Over the past 10 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to bring you the latest […]
IWHM6 | Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models
September 29, 2022
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will attend the 6th International Workshop on Humanized Mice (IWHM6) held in Kyoto University, Japan, from October 12 to 14, 2022. The company will present 12 posters on humanized animal models independently developed by its sub brand BioMice, including 8 target humanized mice and 3 second-generation immunodeficient […]
Research Impact: B-NDG Mice Used to Identify Lipid Transport Mechanism Driving T Cell Leukemogenesis
September 29, 2022
By John Charpentier, Ph.D. September 29, 2022 A recent study featuring Biocytogen mice identifies a non-vesicular lipid transport mechanism required for T cell leukemogenesis. Wenbing Zhong and colleagues at Jinan University in Guangzhou, China report that a lipid binding protein called ORP4L, which is expressed in adult T cell leukemia (ATL) cells but not normal […]
Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress
September 27, 2022
Biocytogen will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM–based fully human antibody discovery platforms: RenMabTM-based monoclonal antibody platform, RenLite®-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform Progress of Project Integrum, a large-scale project to develop antibody therapeutics […]
Breakfast & Biotech with Biocytogen
September 21, 2022
Biocytogen eagerly invites fellow industrial partners and colleagues to join us for a Biotech and Breakfast session at the MassBio Hub. About this event Therapeutic antibodies represent an increasing share of new drug approvals and a current global market well in excess of $100B. Their research and development, however, is fraught with significant risks and […]
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy
September 15, 2022
Beijing and Guangzhou, China, September 15, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed […]
Webinar: Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen
September 13, 2022
Our webinar “Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen” was live on Sep 29, 2022 at 1PM EDT. An understanding of the exposure-response relationship is critical to advancing the development of therapeutic candidates. Pharmacokinetics (PK), the measure of drug absorption, distribution, and excretion over time, is one dimension of this relationship. Pharmacodynamics (PD), […]
Research Impact: Custom Biocytogen mouse models used to identify critical mediator of inflammation-driven metastases
September 7, 2022
By John Charpentier, Ph.D. September 7, 2022 While metastases are ultimately responsible for the large majority of cancer deaths, most oncology drugs in development target primary tumors, and few specifically prevent metastasis. Although surgical resection of solid tumors is an effective early treatment intervention, the resulting inflammation can promote metastasis by increasing adhesion of circulating […]
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs
September 1, 2022
Beijing, China, September 1, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of […]
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
August 30, 2022
Beijing, China and San Diego, CA, August 29, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with […]
